Table 1.
Participant characteristics
| n (%) N= 162 | |
|---|---|
| Demographics | |
| Mean Age (range) | 31 (20–45) |
| Race: White | 158 (97) |
| Ethnicity: Hispanic | 10 (6) |
| Education: College and above | 4.7 (10) |
| Relationship status: Married or cohabiting | 149 (92) |
| Religious affiliation: Any | 107 (66) |
| Employment status | |
| Working | 94 (58) |
| Disability | 28 (17) |
| Student | 21 (13) |
| Non-working | 19 (12) |
| Insurance type | |
| Private | 130 (80) |
| Public (Medicare or Medicaid) | 18 (11) |
| Uninsured | 14 (9) |
| IBD History | |
| Diagnosis | |
| Ulcerative colitis | 61 (38) |
| Crohn's disease | 101 (62) |
| Previous IBD-related surgery | 90 (56) |
| Current IBD medication use | 120 (74) |
| Aminosalicylates | 50 (31) |
| Immunomodulators | 37 (23) |
| Topical steroids | 5 (3) |
| Systemic steroids | 27 (17) |
| Biologic therapies | 60 (37) |
| Past IBD medication use | |
| Aminosalicylates | 132 (82) |
| Immunomodulators | 100 (62) |
| Topical steroids | 42 (26) |
| Systemic steroids | 135 (83) |
| Biologic therapies | 80 (49) |
| Reproductive characteristics | |
| Median parity (range) | 0 (0–6) |
| Contraceptive method by World Health Organization Efficacy Tier | |
| No Method | 38 (23) |
| Tier 1 (sterilization, IUD, or implant) | 27 (17) |
| Tier 2 (short-term hormonal methods) | 66 (41) |
| Tier 3 (barrier methods) | 27 (17) |
| Tier 4 (behavioral methods) | 4 (2) |
IBD = Inflammatory Bowel Disease; IUD = Intrauterine Device;
IBD medication classes with U.S. Food and Drug Administration (F.D.A.) pregnancy category (A-X):
- Aminosalicylates include balsalazide (B), sulfasalazine (A), mesalamine (C), and olsalazine (C)
- Immunomodulators include azathioprine (D), 6-mercaptopurine (D), and methotrexate (X)
- Topical steroids include hydrocortisone (C) enemas, suppositories, and other formulations
- Systemic steroids include budesonide (B), prednisone (C), methylprednisolone (C), and prednisolone (C)
- Biologic therapies include infliximab (B), adalimumab (B), certolizumab (B), and natalizumab (C)